@article{71440a024f284feab09536b19cacaea6,
title = "College of American Pathologists (CAP) microbiology committee perspective: The need for verification studies",
keywords = "Antimicrobial agents, Susceptibility testing",
author = "Wojewoda, {Christina M.} and Anderson, {Neil W.} and Humphries, {Romney M.} and Martin, {Isabella W.} and Mathison, {Blaine A.} and McMullen, {Allison R.} and Nolte, {Frederick S.} and Peaper, {David R.} and Pillai, {Dylan R.} and Rauch, {Carol A.} and Rhoads, {Dan D.} and Sharp, {Susan E.} and She, {Rosemary C.} and Simner, {Patricia J.} and Sullivan, {Kaede V.} and Theel, {Elitza S.} and Theiss, {Angela M.} and Thomson, {Richard B.} and Pritt, {Bobbi S.}",
note = "Funding Information: ACKNOWLEDGMENTS This letter was submitted with approval from the College of American Pathologists. Dr. Romney M. Humphries is employed by Accelerate Diagnostics, Inc., and owns stocks in the company. Dr. Richard B. Thomson serves as a consultant for Accelerate Diagnostics, Inc., and is the Chair of the Microbiology Expert Panel for the CLSI. Dr. Dan D. Rhoads receives research funding for work on novel antibacterial agents through Shionogi Inc., Tetraphase Pharmaceuticals Inc., and Venatorx Pharmaceuticals. The other authors have no relevant conflicts of interest.",
year = "2020",
doi = "10.1128/JCM.02105-19",
language = "English (US)",
volume = "58",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "4",
}